

Iowa Medicaid Drug Utilization Review (DUR) Commission

November 3, 2021

Location: Teleconference (Due to COVID-19)

Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=md7578ed902348cfab772e1e2b4bc2a29>

Dial In: 1-844-245-7693

Meeting Number: 2536 676 8810

Meeting Password: uFcmZHki879

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) August 2021 DUR Recommendation Letter to DHS
 - c) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Fee-for-Service
 - b) Amerigroup
 - c) Iowa Total Care
 - d) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure.
 - Written - Must submit written comments and a completed conflict of interest disclosure.
 - Reference complete public comment policy [here](#).
 - **All submissions must be received no later than 4:30 p.m. CT October 27, 2021.**
 - Send to info@iadur.org **Indicate in email if providing written comment or verbal comment.**
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Concurrent Opioids and Benzodiazepines – Additional Information
 - ii. Duplicate PPIs

- iii. Chronic Use of Controlled Sedative/Hypnotic Agents
- iv. Montelukast for Allergic Rhinitis
- b) Proposal(s)
 - i. Concurrent use of GLP-1 RA and DPP-4 Inhibitors
 - ii. High Dose Glucocorticoid without Bisphosphonate
- c) Commission Recommendations for Retrospective DUR Agenda Topics
- 7. Prospective DUR
 - a) Review of Current Oral Benzodiazepine Quantity Limits
- 8. Break (10 minutes)
- 9. Prior Authorization
 - a) Annual Review of Prior Authorization (PA) Criteria
 - b) Select Preventative Migraine Treatments – Initial Review
 - c) Hepatitis C Treatments – Initial Review
 - d) Janus Kinase Inhibitors – Initial Review
 - e) Apremilast (Otezla) – Initial Review
 - f) Biologicals for Arthritis – Initial Review
 - g) Triheptanoin (Dojolvi) – Initial Review
 - h) Baclofen Oral Solution (Ozobax) – Initial Review
 - i) Topical Acne and Rosacea Products – Second Review
 - j) Omalizumab (Xolair) – Second Review
 - k) Vericiguat (Verquvo) – Second Review
 - l) Viloxazine (Qelbree) – Second Review
 - m) Non-Biologic Agents for Ulcerative Colitis – Second Review
 - n) Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, Oral – Second Review
- 10. Miscellaneous
 - a) DUR Digest Vol. 34, No. 1 – Initial Review
 - b) MedWatch

[FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment](#)

[FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions](#)

[FDA Approves Drug for Schizophrenia to be Administered at a Six Month Interval](#)

[FDA approves add-on drug for ages 10 & up with rare forms of high cholesterol](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to

the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

**Next Meeting
February 2, 2022
Location TBD**